*Disseminated on Behalf of Medicus Pharma Ltd.
Krypton Street Just Announced (MDCX) Is Back On The Radar!
Full Coverage Starting Tomorrow Morning—Monday, December 8, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Take A Look At (MDCX) Before Tomorrow Morning…
December 7, 2025
Heads Up Tonight | See Why (MDCX) Just Shot Back Onto Tomorrow's Radar Dear Reader, Every now and then, you spot a setup that doesn't just whisper for attention—it leans in and grabs the front of your shirt. Momentum, timing, fresh potential catalysts… all tightening at once. And now, one more spark just hit the wire. Late Friday, (MDCX) revealed a warrant-inducement agreement that delivers roughly $5.1M in immediate capital—strengthening the balance sheet without adding heavy dilution, since the exercised warrants were already part of the fully diluted structure. In exchange, the company issued long-dated warrants at $2, a move that reinforces confidence in where leadership believes this story is heading. Layer that fresh cash on top of everything else building here, and the picture sharpens even more. That's exactly what's happening right now with Medicus Pharma Ltd. (NASDAQ: MDCX). We've covered this profile before, but the latest sequence of developments has pushed it right back onto our radar heading into Monday morning, December 8, 2025—and the timing couldn't be more interesting. Keep in mind, (MDCX) is working with an ultra-thin float of under 8M shares according to MarketWatch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. Just last week, (MDCX) made an approximate 34% move in under 24 hours, between December 3 and December 4. Add in insider ownership north of 35%—the kind of alignment that often signals confidence behind the scenes—and you can see why momentum watchers are paying attention again. All signs point to a setup worth a closer look. Analyst Targets Suggests Over 1,200% Upside Potential
From Recent Range…
Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 1,200% upside potential from its recent $1.75 range. That's not the only target now in play. Brookline Capital's Kumaraguru Raja recently raised his target from $12 to $20, while Maxim Group's Jason McCarthy reiterated a $20 target in a report published a few days ago—reflecting continued confidence and over 900% upside potential from current levels. Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs. With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning's session. FDA Clears Streamlined Path for SkinJect's Next Phase
Medicus Pharma Ltd. (NASDAQ: MDCX) received positive Type C meeting feedback from the U.S. FDA for its SkinJect program—a dissolvable microneedle patch being developed to non-invasively treat basal cell carcinoma (BCC). The agency confirmed that the program may follow the streamlined 505(b)(2) pathway, potentially reducing both cost and development time, and also offered guidance on study design, endpoints, and formulation improvements, including an adhesive layer and applicator system. (MDCX) is advancing two Phase 2 trials: SKNJCT-003 in the U.S., now over 75% enrolled following a strong interim readout, and SKNJCT-004 across six clinical sites abroad. Enrollment for SKNJCT-003 is expected to complete before the end of Q4 2025, with an End-of-Phase-2 FDA meeting targeted for Q1 2026. The company estimates the market for non-invasive BCC treatments could approach $2B annually. Executive Chairman and CEO Dr. Raza Bokhari noted that the FDA's feedback "marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC," reinforcing growing confidence as development advances. (MDCX) Opens New Pathway for Patients With
Compassionate Use Partnership
Medicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA) to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide. The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision. The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development. Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)'s mission to bring targeted innovation to conditions with significant unmet medical needs. First Patient Treated in UAE Marks Key Milestone in
Global Phase 2 Expansion Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC). Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai. The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio. According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone "marks an important step in expanding Medicus's clinical footprint beyond the U.S.," underscoring the company's push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential. (MDCX) Bolsters Clinical Portfolio With Teverelix
—A Dual-Use Phase 2b Candidate Medicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer. The move broadens (MDCX)'s clinical scope into two therapeutic areas with a combined $6B market potential.
Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients. In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies. The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board. Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need. Recent Developments
Dec 01, 2025 – Appointment of Carolyn Bonner as Chief Financial Officer
Medicus promoted its President, Carolyn Bonner, to Chief Financial Officer, strengthening its executive leadership as the company scales its clinical, regulatory, and future commercial operations. Her expanded role is expected to support Medicus through its next phase of growth. Nov 24, 2025 – Company Highlights Expanded Innovation Across Skin and Prostate Cancer Programs
Medicus released an in-depth update showcasing the strategic value of both its SkinJect D-MNA platform for BCC and its late-stage Teverelix program addressing high-need prostate cancer and acute urinary retention. The company emphasized its multi-market pipeline expansion and growing clinical footprint. Nov 17, 2025 – FDA CNPV Application Filed for SkinJect (SKNJCT-003)
Medicus submitted its Commissioner's National Priority Voucher (CNPV) application for SkinJect, positioning the program for a potential 1–2 month FDA review instead of the standard 10–12 months. The application highlights SkinJect's alignment with national priorities such as affordability, access, domestic manufacturing, public-health impact, and rare-disease relevance, including Gorlin Syndrome. Nov 14, 2025 – Q3 2025 Corporate Update & Financial Highlights
Medicus reported continued progress across its SkinJect and Teverelix programs, expanded trial activity in the U.S., U.K., and UAE, and strengthened patient-access initiatives through the Gorlin Syndrome Alliance. The company also improved its balance sheet with $10.4M in new capital and reaffirmed confidence in its growing global clinical footprint. 7 Reasons Why (MDCX) Is Topping Our Watchlist Tomorrow Morning
—Monday, December 8, 2025
1. Limited Float: with fewer than 8M shares available, (MDCX)'s small float has the potential for big moves if demand begins to shift. 2. Recent Momentum: the chart for (MDCX) showcases an approximate 34% move in under 24 hours last week. 3. Analyst Coverage: fresh coverage has placed (MDCX) as high as $27, signaling over 1,200% upside potential relative to its recent $2 range. 4. Insider Confidence: leadership continues to hold more than 35% of (MDCX)'s float, reinforcing long-term confidence behind the scenes. 5. Regulatory Boost: recent FDA Type C feedback has given (MDCX)'s SkinJect program a clearer and potentially faster 505(b)(2) route. 6. Global Progress: new clinical activity across U.S., U.K., and UAE sites shows (MDCX) expanding its SkinJect program on multiple fronts. 7. Expanded Pipeline: following the Antev acquisition, (MDCX) now holds two late-stage therapeutic programs—SkinJect and Teverelix—each targeting high-need medical conditions. All seven factors point to one conclusion—(MDCX) is entering a decisive stretch. With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar. Take A Look At (MDCX) Before Tomorrow Morning…
With all of these forces stacking at once, (MDCX) sits in a rare position—one shaped by a float under 8M shares, a chart that has already produced multiple sharp overnight moves, and analyst targets stretching as high as $27 from its recent $1.75 range, which suggest over 1,200% upside potential.
Add in leadership holding more than a third of the float, fresh FDA alignment on a streamlined regulatory path, expanding Phase 2 activity across three regions, and a broadened pipeline now anchored by two late-stage programs… and it becomes clear why this name refuses to drift quietly into the background. We will have all eyes on (MDCX) tomorrow morning. Take a look at (MDCX) before you call it a night. Also, keep a lookout for my morning update. Have a good night. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
Tidak ada komentar:
Posting Komentar